Head to Head Survey: Verenium (VRNM) and Its Rivals
Verenium (NASDAQ: VRNM) is one of 32 publicly-traded companies in the “Commodity Chemicals” industry, but how does it weigh in compared to its competitors? We will compare Verenium to similar companies based on the strength of its valuation, earnings, risk, profitability, dividends, analyst recommendations and institutional ownership.
Volatility and Risk
Verenium has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Verenium’s competitors have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.
This table compares Verenium and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Verenium and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Verenium Competitors||$4.01 billion||$340.26 million||134.02|
Verenium’s competitors have higher revenue and earnings than Verenium. Verenium is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
70.9% of shares of all “Commodity Chemicals” companies are held by institutional investors. 7.8% of shares of all “Commodity Chemicals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This is a breakdown of recent recommendations and price targets for Verenium and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Commodity Chemicals” companies have a potential downside of 0.48%. Given Verenium’s competitors higher probable upside, analysts plainly believe Verenium has less favorable growth aspects than its competitors.
Verenium competitors beat Verenium on 7 of the 8 factors compared.
Verenium Corporation (Verenium) is an industrial biotechnology company. The Company develops and commercializes enzymes for use in a range of industrial processes. It manufactures and markets its enzyme products in the fields of animal health and nutrition, grain processing, oilfield services and other industrial processes, such as pulp and paper and textiles. As of December 31, 2012, it marketed commercial enzyme products, either independently or in collaboration with its partners. In addition, it has developed a pipeline of enzyme product candidates. Its products are organized into four product lines: animal health and nutrition, grain processing, oilfield services and other industrial processes. As of December 31, 2012, it markets nine commercial enzyme products. In October 2013, BASF SE acquired 71% stake in the Company.
Receive News & Ratings for Verenium Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verenium Corp and related companies with MarketBeat.com's FREE daily email newsletter.